Biotest AG to Delist Shares from Frankfurt Stock Exchange

Biotest AG has announced the delisting of its shares from the Frankfurt Stock Exchange, effective on 6 June 2025. This decision follows approval from the Frankfurt Stock Exchange to revoke the admission of Biotest's ordinary and preference shares from trading on the regulated market and its Prime Standard segment.

The delisting coincides with the conclusion of the acceptance period for Grifols Biotest Holdings GmbH’s public delisting offer. Post-6 June 2025, Biotest shares will no longer be traded on the Frankfurt Stock Exchange, and the associated listing requirements will cease to apply.

This move marks a significant step for Biotest AG, a company specializing in biological therapeutics derived from human plasma, now part of the Grifols Group since May 2022. Investors and stakeholders are advised to stay informed about further developments.